Improved glycemic control in mice lacking Sglt1 and Sglt2

American Journal of Physiology - Endocrinology and Metabolism

Volumn 304, Issue 2, 2013, Pages

  Powell, David R ^a   DaCosta, Christopher M ^a   Gay, Jason ^a   Ding, Zhi Ming ^a   Smith, Melinda ^a   Greer, Jennifer ^a   Doree, Deon ^a   Jeter Jones, Sabrina ^a   Mseeh, Faika ^a   Rodriguez, Lawrence A ^a   Harris, Angela ^a   Buhring, Lindsey ^a   Platt, Kenneth A ^a   Vogel, Peter ^a   Brommage, Robert ^a   Shadoan, Melanie K ^a   Sands, Arthur T ^a   Zambrowicz, Brian ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

Diabetes; GLP 1; Knockout; SGLT1; SGLT2

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL EXPERIMENT; ARTICLE; GLUCOSE ABSORPTION; GLUCOSE METABOLISM; GLUCOSURIA; GLYCEMIC CONTROL; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; STREPTOZOCIN DIABETES; WILD TYPE;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; GLYCOSURIA; INSULIN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; STREPTOZOCIN;

EID: 84872407235     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00439.2012     Document Type: Article

References (58)

1. Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, Kitamura K, Matsumoto M, Saito A. Improved diabetic syndrome in C57BL/KsJdb/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 132: 578-586, 2001.
2. Barfuss DW, Schafer JA. Differences in active and passive glucose transport along the proximal nephron. Am J Physiol Renal Fluid Electrolyte Physiol 241: F322-F332, 1981.
3. Beltrandelrio H, Kern F, Lanthorn T, Oravecz T, Piggott J, Powell D, Ramirez-Solis R, Sands AT, Zambrowicz B. Saturation screening of the druggable mammalian genome. In: Model Organisms in Drug Discovery, edited by P. M. Carroll and K. Fitzgerald). Chichester, UK: Wiley & Sons, 2003, p. 251-278.
4. Brommage R, Desai U, Revelli JP, Donoviel D, Fontenot G, DaCosta C, Smith D, Plat K, Hansen G, Sands A, Zambrowicz B, Powell DR. High-throughput screening of mouse knockout lines identifies true lean and obese phenotypes. Obesity 16: 2362-2367, 2008.
5. Calado J, Sznajer Y, Metzger D, Rita A, Hogan MC, Kattamis A, Scharf M, Tasic V, Greil J, Brinkert F, Kemper MJ, Santer R. Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol Dial Transplant 23: 3874-3879, 2008.
6. Chao EC, Henry RR. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov 9: 551-559, 2010.
7. Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 1: 57-92, 2010.
8. Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, Ways K, Schwartz S. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 14: 539-545, 2012.
9. Donoviel DB, Freed DD, Vogel H, Potter DG, Hawkins E, Barrish JP, Mathur BN, Turner CA, Geske R, Montgomery CA, Starbuck M, Brandt M, Gupta A, Ramirez-Solis R, Zambrowicz BP, Powell DR. Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN. Mol Cell Biol 21: 4829-4836, 2001.
10. Frohnert PP, Höhmann B, Zwiebel R, Baumann K. Free flow micropuncture studies of glucose transport in the rat nephron. Pflügers Arch 315: 66-85, 1970.
11. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective lowaffinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 327: 268-276, 2008.
12. Fujimori Y, Katsuno K, Ojima K, Nakashima I, Nakano S, Ishikawa-Takemura Y, Kusama H, Isaji M. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 609: 148-154, 2009.
13. Gorboulev V, Schürmann A, Vallon V, Kipp H, Jaschke A, Klessen D, Friedrich A, Scherneck S, Rieg T, Cunard R, Veyhl-Wichmann M, Srinivasan A, Balen D, Breljak D, Rexhepaj R, Parker HE, Gribble FM, Reimann F, Lang F, Wiese S, Sabolic I, Sendtner M, Koepsell H. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61: 187-196, 2012.
14. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57: 1723-1729, 2008.
15. +/glucose co-transporter. Nature 330: 379-381, 1987.
16. Henning SJ. Biochemistry of intestinal development. Environ Health Perspect 33: 9-16, 1979.
17. +/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 300: C14-C21, 2011.
18. +/glucose cotransporter (SGLT1) in the small intestine. J Control Release 125: 42-49, 2008.
19. Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, Pongratz RL, Zhao X, Moeckel GW, Samuel VT, Whaley JM, Shul-man GI, Kibbey RG. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60: 890-898, 2011.
20. +/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93: 397-404, 1994.
21. Katsuno K, Fujimori Y, Ishikawa-Takemura Y, Isaji M. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur J Pharmacol 618: 98-104, 2009.
22. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 85: 513-519, 2009.
23. Lee EC, Desai U, Gololobov G, Hong S, Feng X, Yu XC, Gay J, Wilganowski N, Gao C, Du LL, Chen J, Hu Y, Zhao S, Kirkpatrick L, Schneider M, Zambrowicz BP, Landes G, Powell DR, Sonnenburg WK. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3), and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL). J Biol Chem 284: 13735-13745, 2009.
24. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32: 650-657, 2009.
25. Ljunggren O, Bolinder J, Johansson L, Wilding J, Langkilde AM, Sjöström CD, Sugg J, Parikh S. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 14: 990-999, 2012.
26. Longo WE, Ballantyne GH, Savoca PE, Adrian TE, Bilchik AJ, Modlin IM. Short-chain fatty acid release of peptide YY in the isolated rabbit distal colon. Scand J Gastroenterol 26: 442-428, 1991.
27. Ly JP, Onay T, Sison K, Sivaskandarajah G, Sabbisetti V, Li L, Bonventre JV, Flenniken A, Paragas N, Barasch JM, Adamson SL, Osborne L, Rossant J, Schnermann J, Quaggin SE. The Sweet Pee model for Sglt2 mutation. J Am Soc Nephrol 22: 113-123, 2011.
28. +/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nat Genet 12: 216-220, 1996.
29. McSherry NR, Wen SF. Segmental analysis of renal glucose transport in young female rats. J Physiol 356: 9-19, 1984.
30. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414: 821-827, 2001.
31. Moriya R, Shirakura T, Ito J, Mashiko S, Seo T. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am J Physiol Endocrinol Metab 297: E1358-E1365, 2009.
32. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med Early Online: 1-19, 2011.
33. Oemar BS, Byrd DJ, Brodehl J. Complete absence of tubular glucose reabsorption: a new type of renal glucosuria (type 0). Clin Nephrol 27: 156-160, 1987.
34. +-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48: 1794-1800, 1999.
35. Qi Z, Whitt I, Mehta A, Jin J, Zhao M, Harris RC, Fogo AB, Breyer MD. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 286: F590-F596, 2004.
36. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. Glucose sensing in L cells: a primary cell study. Cell Metab 8: 532-539, 2008.
37. Revelli JP, Smith D, Allen J, Jeter-Jones S, Shadoan M, Desai U, Schneider M, van Sligtenhorst I, Kirkpatrick L, Platt K, Suwanichkul A, Savelieva K, Gerhardt B, Mitchell J, Syrewicz J, Zambrowicz B, Hamman BD, Vogel P, Powell DR. Profound obesity secondary to hyperphagia in mice lacking kinase suppressor of Ras 2. Obesity 19: 1010-1018, 2011.
38. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev CD006739, 2008.
39. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79: 1510-1515, 1987.
40. Sakuma S, Teraoka Y, Sagawa T, Masaoka Y, Kataoka M, Yamashita S, Shirasaka Y, Tamai I, Ikumi Y, Kida T, Akashi M. Carboxyl group-terminated polyamidoamine dendrimers bearing glucosides inhibit intestinal hexose transporter-mediated D-glucose uptake. Eur J Pharm Biopharm 75: 366-374, 2010.
41. Samtani MN. Simple pharmacometric tools for oral anti-diabetic drug development: competitive landscape for oral non-insulin therapies in type 2 diabetes. Biopharm Drug Dispos 31: 162-177, 2010.
42. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, Li Volti S, Neuhaus T, Skovby F, Swift PG, Schaub J, Klaerke D. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14: 2873-2882, 2003.
43. Scholl-Burgi S, Santer R, Ehrich JHH. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dial Transplant 19: 2394-2396, 2004.
44. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev CD006423, 2011.
45. Suzuki M, Honda K, Fukazawa M, Ozawa K, Hagita H, Kawai T, Takeda M, Yata T, Kawai M, Fukuzawa T, Kobayash T, Sato T, Kawabe Y, Ikeda S. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 341: 692-701, 2012.
46. Tahrani AA, Barnett AH. Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. Diabetes Ther 1: 45-56, 2010.
47. Tune BM, Burg MB. Glucose transport by proximal renal tubules. Am J Physiol 221: 580-585, 1971.
48. Turner RJ, Moran A. Further studies of proximal tubular brush border membrane D-glucose transport heterogeneity. J Membr Biol 70: 37-45, 1982.
49. Turner RJ, Moran A. Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies. Am J Physiol Renal Fluid Electrolyte Physiol 242: F406-F414, 1982.
50. +-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci 76: 2655-2668, 2005.
51. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, Koepsell H, Rieg T. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22: 104-112, 2011.
52. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 91: 733-794, 2011.
53. Zambrowicz BP, Abuin A, Ramirez-Solis R, Richter LJ, Piggott J, BeltrandelRio H, Buxton EC, Edwards J, Finch RA, Friddle CJ, Gupta A, Hansen G, Hu Y, Huang W, Jaing C, Key BW Jr, Kipp P, Kohlhauff B, Ma ZQ, Markesich D, Payne R, Potter DG, Qian N, Shaw J, Schrick J, Shi ZZ, Sparks MJ, Van Sligtenhorst I, Vogel P, Walke W, Xu N, Zhu Q, Person C, Sands AT. Wnk1 kinase deficiency lowers blood pressure in mice: A gene-trap screen to identify potential targets for therapeutic intervention. Proc Natl Acad Sci USA 100: 14109-14114, 2003.
54. Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J, Ruff D, Shadoan M, Banks P, Mseeh F, Rawlins DB, Goodwin NC, Mabon R, Harrison BA, Wilson A, Sands A, Powell DR. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 92: 158-169, 2012.
55. Zambrowicz BP, Friedrich GA, Buxton EC, Lilleberg SL, Person C, Sands AT. Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells. Nature 392: 608-611, 1998.
56. Zambrowicz BP, Sands AT. Knockouts model the 100 best-selling drugs-will they model the next 100? Nat Rev Drug Discov 2: 38-51, 2003.
57. Zhang W, Rajan I, Savelieva KV, Wang CY, Vogel P, Kelly M, Xu N, Hasson B, Jarman W, Lanthorn TH. Netrin-G2 and netrin-G2 ligand are both required for normal auditory responsiveness. Genes Brain Behav 7: 385-392, 2008.
58. Zhou J, Martin RJ, Tulley R, Raggio AM, McCutcheon KL, Shen L, Danna SC, Tripathy S, Hegsted M, Keenan MJ. Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am J Physiol Endocrinol Metab 295: E1160-E1166, 2008.